This report describes the global market size of Alpha Emitters from 2019 to 2022 and its CAGR from 2019 to 2023, and also forecasts its market size to the end of 2031 and its expected to grow with a CAGR of 37.3% from 2024 to 2031.
Due to the COVID-19 pandemic, the global market for Alpha Emitters estimated at US 34.10 $ billion in the year 2023, is projected to reach a revised size of US 562.97$ million by 2031, growing at a CAGR of 37.3% during the forecast period 2024-2031.
Alpha emitters are a class of radioactive substances that release alpha particleshighly energetic, positively charged particlesduring radioactive decay. These particles have a short range and limited penetration, usually only a few micrometers, which makes them ideal for targeted therapies, such as alpha-particle radiotherapy for cancer. By delivering concentrated energy directly to cancer cells, alpha emitters can effectively destroy tumors while minimizing collateral damage to surrounding healthy tissue. Their precision and potency have made them a focus of research in both medical and environmental applications. However, handling alpha emitters requires strict safety protocols due to their high radioactivity.
For geography segment, regional supply, demand, major players, price is presented from 2019 to 2031. This report cover following regions:
North America
Asia-Pacific
Europe
Middle East and Africa
South America
The key countries for each regions are also included such as United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.
For competitor segment, the report include global key players of Alpha Emitters as well as some small players. The information for each competitor include:
Company Profile
Main Business Information
SWOT Analysis
Sales Volume, Revenue, Price and Gross Margin
Market Share
By Type of Radionuclide
Radium-223
Actinium-225
Lead-212
Bismuth-213
Astatine-211
Terbium-149
Thorium-227
Alpha emitters are segmented by type based on their source isotope, half-life, and therapeutic applications. Key types include Radium-223, used primarily for treating bone metastases due to its calcium-mimicking properties; Actinium-225, favored for targeted alpha-particle therapy (TAT) in various cancers with its longer half-life; Thorium-227, a precursor to Radium-223, utilized for in situ alpha particle generation; Astatine-211, with a short half-life, ideal for precise targeting of smaller tumors; and Lead-212, which generates Bismuth-212, used in radioimmunotherapy, especially for blood cancers. Each type is selected based on its unique properties that match specific medical needs, balancing factors like decay rate, energy release, and tissue targeting.
By Application
Prostate Cancer
Bone Metastasis
Breast Cancer
Pancreatic Cancer
Ovarian Cancer
Lung Cancer
Others (such as melanoma, lymphomas)
Alpha emitters are increasingly utilized in the treatment of various cancers, offering a highly targeted form of radiotherapy. In prostate cancer, Radium-223 is widely used, particularly for cases where the cancer has spread to the bones, as it mimics calcium and selectively targets bone metastases. Bone metastasis from other cancers, such as breast or lung cancer, also benefits from Radium-223, which helps in reducing pain and improving patient outcomes.
For breast cancer, especially when metastasized to the bones, alpha emitters provide a focused approach to destroy cancerous cells while minimizing damage to healthy tissue. Pancreatic cancer treatments leverage alpha emitters like Actinium-225 for their ability to precisely target tumor cells, addressing this aggressive cancer with minimal collateral damage. In ovarian cancer, alpha emitters are used in advanced stages to target resistant cancer cells effectively. Lung cancer treatment, particularly for aggressive forms, benefits from alpha emitters' ability to eradicate micro-metastases with high precision. Additionally, in other cancers such as melanoma and lymphomas, alpha emitters are being explored for their potential to offer targeted treatment options where conventional therapies have limited efficacy. These applications highlight the versatility and effectiveness of alpha emitters in oncology.
By End-User
Hospitals
Cancer Research Institutes
Ambulatory Surgical Centers
Radiation Therapy Centers
Alpha emitters are utilized by various end-users, each playing a critical role in the delivery of targeted radiotherapy. Hospitals are the primary end-users, where alpha emitters are integrated into oncology departments to treat a wide range of cancers, providing in-patient and out-patient care. Cancer research institutes focus on developing and refining alpha-emitter therapies, conducting clinical trials to explore new applications and improve treatment efficacy. Ambulatory surgical centers utilize alpha emitters in outpatient settings, offering minimally invasive procedures for cancer treatment, allowing patients to receive therapy without extended hospital stays. Radiation therapy centers are specialized facilities where alpha emitters are employed for precise cancer treatment, often in collaboration with hospitals and research institutes, focusing on delivering high doses of radiation directly to tumors while sparing healthy tissue. These end-users collectively enhance the accessibility, research, and application of alpha-emitter therapies in cancer care.
By Therapeutic Modality
Targeted Alpha Therapy (TAT)
Alpha-Immunotherapy
Radiopharmaceutical Therapy
Alpha emitters are used in various therapeutic modalities to target and treat cancer with high precision. Targeted Alpha Therapy (TAT) involves using alpha-emitting isotopes that bind specifically to cancer cells, delivering potent radiation directly to the tumor while minimizing damage to surrounding healthy tissue. This modality is highly effective for cancers with specific cell surface markers, allowing for precise and localized treatment.Alpha-immunotherapy combines alpha emitters with antibodies that specifically target cancer cells, enhancing the selectivity and effectiveness of the treatment. The antibodies guide the alpha particles directly to the cancer cells, allowing for targeted destruction of tumors while sparing normal cells. Radiopharmaceutical Therapy involves incorporating alpha emitters into pharmaceutical compounds that are either absorbed by or bind to cancerous cells. This approach can target a broad range of cancers, including those that are difficult to treat with conventional therapies, by delivering radiation directly to the tumor site via systemic administration. Each modality leverages the unique properties of alpha emitters to improve cancer treatment outcomes through targeted and efficient radiation delivery.
Key players
Bayer AG
Actinium Pharmaceuticals, Inc.
RadioMedix, Inc.
IBA Radiopharma Solutions
Telix Pharmaceuticals
Eckert & Ziegler Radiopharma GmbH
Fusion Pharmaceuticals
Orano Med
Nordion (Canada) Inc.
Viewpoint Molecular Targeting
Please ask for sample pages for full companies list
Base Year: 2023
Historical Data: from 2019 to 2023
Forecast Data: from 2024 to 2031
Any special requirements about this report, please let us know and we can provide custom report.
"
Global Albumin Market
Global Surgical Equipment Market
Global Interventional Oncology Market
Global Brain-Computer Interface (BCI) Market
Europe Hormone Replacement Therapy Market
Global Medical Tubing Market
Global Gene Silencing Market
Europe Veterinary 3D Printing Market
Global Beauty Supplements Market
Global Human Organoid Market
Your phrase has been sent to nick's email. Once he takes action. you will be notified!
Stats And Research ™ Copyright © 2025 .
